New Data From REZOLVE-AD Study Of Rezpegaldesleukin Presented In Late-Breaking Oral Abstract Presentation At ACAAI 2025 Annual Scientific Meeting. Statistically significant and clinically meaningful i ...
ORLANDO -- Anti-interleukin (IL)-5 receptor alpha monoclonal antibody benralizumab (Fasenra) reduced flares in ...
TipRanks on MSN
Intellia Therapeutics presents Phase 1/2 data on lonvo-z
Intellia Therapeutics (NTLA) presented positive clinical data from a pooled analysis of all patients who received a 50 milligram dose of lonvo-z ...
(GLOBE NEWSWIRE) -- (NASDAQ: NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today presented positive clinical data from a pooled ...
Expert Consumers has recognized Forme® as a leading innovator in smart posture correction technology, acknowledging the company's advancements in addressing spinal conditions such as kyphosis, round ...
Hypereosinophilic syndrome (HES) is a heterogeneous disorder characterised by persistent, abnormal eosinophil elevation in ...
TipRanks on MSN
Nektar presents new data from REZOLVE-AD study of ACAAI
Therapeutics presented new data from the ongoing REZOLVE-AD Phase 2b study in a late-breaking oral abstract presentation at the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback